BMS-103
BMS-103 is a PDL1 inhibitor (IC50 = 79.1 nM) (kd = 44 nM) . BMS-103 reduces the survival rate of acute T-lymphoblastic leukemia cells and ovarian cells. BMS-103 can be used in research on acute T-lymphoblastic leukemia and cancers such as ovarian cancer[1].
Product Specifications
CAS Number
1675202-86-4
UNSPSC
12352005
Target
PD-1/PD-L1
Related Pathways
Immunology/Inflammation
Field of Research
Cancer
Smiles
CC1=C(COC2=CC(OC)=C(CNCCO)C(OC)=C2)C=CC=C1C3=CC=CC=C3
Molecular Formula
C25H29NO4
Molecular Weight
407.50
References & Citations
[1]anesan A, et al. Comprehensive in vitro characterization of PD-L1 small molecule inhibitors. Sci Rep. 2019 Aug 27;9 (1) :12392. d
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
46329061 1.0 µg DNA
TCEAL3-AS1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)
Sign In for Pricing
View Details 
